Crohns Disease Diagnostic & Therapeutic Market Size
| Study Period: | 2018 - 2028 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 3.1 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and it's growth?
Crohns Disease Diagnostic & Therapeutic Market Analysis
The Crohn's disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period.
With the rise in COVID-19, the prevalence of other related complications also increased. According to a report by the SECURE-IBD database in January 2022, adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with IBD. The novel severe acute respiratory syndrome-related coronavirus activated innate and adaptive immune responses upon entering the gastrointestinal tract. The study shows IBD patients' inflammatory reactions may cause intestinal damage. Also, a research article published in the Journal of Crohn and Colitis in March 2020 showed that IBD patients undertaking immune suppressors are associated with a greater risk of infections, even though there is no evidence to suggest that COVID-19 affects IBD patients more commonly than the general population. According to a review article in the World Journal of Gastroenterology in October 2020, it was comprehended that many COVID-19 patients were found to develop gastrointestinal complaints. Thus, there is an increasing demand for the Crohn's disease diagnostics and therapeutics market to manage further complications that could develop due to COVID-19.
The increasing occurrence of Crohn’s disease is the primary driver predicted to boost the growth of the market. According to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD is around 7 million worldwide. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney, and liver diseases are higher in IBD patients than in non-IBD patients. In the older population (66 years and above), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30-day readmissions, and more extended hospital stays. Studies on the treatment of IBD for the prevention of such instances are a great boost to the development of the market during the forecast period.
The increasing awareness of Crohn's disease, coupled with rising initiatives by regulatory bodies to develop novel treatment options, is expected to provide the market studied with high growth potential.
Crohns Disease Diagnostic & Therapeutic Industry Segmentation
Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from the mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors in genetically predisposed individuals.
The Crohn’s disease diagnostics and therapeutics market is segmented by diagnostics (blood test, fecal test, colonoscopy, flexible sigmoidoscopy, computerized tomography, magnetic resonance imaging, capsule endoscopy, other diagnostic tests), treatment (medication (anti-inflammatory agents, immunosuppressants, analgesics and antipyretics, other medications), surgery), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value in USD million for the above segments.
| By Diagnostics | |
| Blood Test | |
| Fecal Test | |
| Colonoscopy | |
| Flexible Sigmoidoscopy | |
| Computerised Tomography | |
| Magnetic Resonance Imaging | |
| Other Diagnostic Tests |
| By Treatment | ||||||
| ||||||
| Surgery |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Crohns Disease Diagnostic & Therapeutic Market Trends
This section covers the major market trends shaping the Crohns Disease Diagnostic & Therapeutic Market according to our research experts:
The Anti-inflammatory Agents Segment is Expected to Witness Significant Growth During the Forecast Period
Anti-inflammatory agents have continued to lead as the largest sub-segment under the market's therapeutics segment due to their higher efficacy than immunosuppressants and analgesics. A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for Crohn's disease.
Additionally, the increasing investments, clinical trials, and key player activities are expected to contribute to the growth of the segment studied. For instance, in September 2022, rise therapeutics LLC received funding from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institute of Health to support proof-of-concept clinical testing of the therapeutic candidate, R-3750. It is an anti-inflammatory drug for the treatment of inflammatory bowel disease.
Similarly, in July 2021, Cerecord had positive initial phase 1 b results for CERC-002 in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments. Thus the abovementioned factors are expected to drive the growth of the segment studied during the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America holds the largest market share in the Crohn's disease diagnostics and therapeutics market due to the increasing prevalence of the disease in the region. The increasing adoption of innovative medicines is expected to drive the demand for the Crohn's disease diagnostics therapeutics market in the North American region. An increase in research and development in clinical-stage companies in novel treatments for the disease is predicted to boost the growth of the Crohn's disease diagnostics therapeutics market in the region. In a study published in the Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in the United States.
In this region, urbanization is a potential factor contributing to the increasing prevalence of Crohn's disease. The incidence of Crohn's disease has been attributed to the “westernization” of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals. Also, the growth strategies of market players, such as partnerships, are expected to contribute to the growth of the market in this region. For instance, in January 2022, LifeArc partnered with the US-based Crohn's and Colitis Foundation to develop a prognostic for Crohn's disease in children. Thus the abovementioned factors are expected to drive the growth of the market in this region during the forecast period.
To understand geography trends, Download Sample Report
Crohns Disease Diagnostic & Therapeutic Industry Overview
The Crohn's disease diagnostics and therapeutics market has growth opportunities in developing and developed nations. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some major market players include Pfizer Inc., Janssen Biotech Inc., GeneTech, Celgene Corporation, AbbVie Inc., and others.
Crohns Disease Diagnostic & Therapeutic Market Leaders
Abbvie Inc.
Celgene Corporation
GeneTech
Janssen Biotech Inc.
Pfizer Inc
*Disclaimer: Major Players sorted in no particular order
Crohns Disease Diagnostic & Therapeutic Market News
- April 2022: Microbiotica received project funding from the Crohn's and Colitis Foundation as a part of their inflammatory bowel disease ventures program for the development of therapies to treat inflammatory bowel disease.
- April 2022: Engitix collaborated with Takeda to expand an existing agreement to include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn's disease.
Crohns Disease Diagnostic & Therapeutic Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
4.2.2 Demand for Prompt Diagnosis
4.2.3 Affected Population Increasing with Time
4.3 Market Restraints
4.3.1 No Specific Treatment or Drug Available in the Market
4.3.2 Lack of Awareness Among People and Symptom Similarity with Other Gastrointestinal Diseases
4.3.3 Lack of Cost-effective Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Diagnostics
5.1.1 Blood Test
5.1.2 Fecal Test
5.1.3 Colonoscopy
5.1.4 Flexible Sigmoidoscopy
5.1.5 Computerised Tomography
5.1.6 Magnetic Resonance Imaging
5.1.7 Other Diagnostic Tests
5.2 By Treatment
5.2.1 Medication
5.2.1.1 Anti-inflammatory Agents
5.2.1.2 Immunosuppressants
5.2.1.3 Analgesics and Antipyretics
5.2.1.4 Other Medications
5.2.2 Surgery
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Celgene Corporation
6.1.3 Genetech
6.1.4 Johnson & Johnson
6.1.5 Pfizer Inc.
6.1.6 Prometheus Laboratories Inc. (Nestle)
6.1.7 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
6.1.8 Takeda's Pharmaceutical Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Crohns Disease Diagnostic & Therapeutic Market Research FAQs
What is the study period of this market?
The Crohn's Disease Diagnostics and Therapeutics Market is studied from 2018 - 2028.
What is the growth rate of Crohn's Disease Diagnostics and Therapeutics Market?
The Crohn's Disease Diagnostics and Therapeutics Market is growing at a CAGR of 3.1% over the next 5 years.
Which region has highest growth rate in Crohn's Disease Diagnostics and Therapeutics Market?
Asia Pacific is growing at the highest CAGR over 2018 - 2028.
Which region has largest share in Crohn's Disease Diagnostics and Therapeutics Market?
North America holds highest share in 2021.
Who are the key players in Crohn's Disease Diagnostics and Therapeutics Market?
Abbvie Inc., Celgene Corporation, GeneTech, Janssen Biotech Inc., Pfizer Inc are the major companies operating in Crohn's Disease Diagnostics and Therapeutics Market.
Crohns Disease Diagnostic & Therapeutic Industry Report
Statistics for the 2023 Crohn's Disease Diagnostic and Therapeutic market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Crohn's Disease Diagnostic and Therapeutic analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
